Psychedelics Research

Providers at Utah's two largest healthcare systems may now treat patients with psilocybin and MDMA as part of a pilot program created by a proposal-turned-law that will take effect as early as May 1, 2024.  The program, open to providers at the University of Utah Health and Intermountain Health,...

On March 20, Congressional leaders at both the House and Senate Appropriations Committees released new spending legislation that would continue blocking Washington D.C.'s legal marijuana sales and fund psychedelic clinical studies. The new Financial Services and General Government legislation...

FDA Grants Cybin Breakthrough Therapy Status For Major Depression Psilocybin Therapy, Company Announces Positive Clinical Data & Canadian $150M Private Placement Clinical-stage psychedelics biopharma company Cybin Inc. (NYSE:CYBN) announced that the Food and Drug Administration has granted...

Welcome to Benzinga's psychedelic headlines roundup. This is our pick of must-read news items concerning the first two weeks of March 2024. See previous edition Psychedelics Headlines: Predicting Readiness, Correcting The Hype, Good And Bad Drugs, Training Programs And More. Research The...

Psilocybin-Assisted Therapy Achieves Positive Clinical Trial Results For Treating Generalized Anxiety Psilocybin-assisted therapy has hit a milestone as clinical trial results show potential benefits for Generalized Anxiety Disorder (GAD.)  With variable symptoms, the condition typically...

Welcome to Benzinga’s psychedelic headlines roundup. This is our pick of must-read news items concerning the last two weeks of February 2024. See previous edition Psychedelics Headlines: Trauma-Informed Care, Valentine’s Day & MDMA, Academics On Drugs Research Validation of the...

The medical psychedelics field stands at a pivotal juncture. With MDMA-assisted therapy close to federal legalization for the treatment of PTSD in the U.S. and other psychedelic substances potentially following suit, these therapies are poised to revolutionize treatment for certain mental health...

Psilocybin-assisted therapy has hit a milestone as clinical trial results show potential benefits for Generalized Anxiety Disorder (GAD.)  With variable symptoms, the condition typically involves a person suffering from excessive anxiety and worry for over six months, potentially causing...

Montreal-based GMP pharmaceutical laboratory CCrest Labs, an R&D collaborator of Ontario-based mushroom company Red Light Holland Corp. (OTCQB:TRUFF), has received a fifth psilocybin import permit to its Canadian controlled drugs and substances dealer’s license.  The new permit...

FDA and Reagan-Udall Foundation are hosting a virtual public meeting on psychedelic research titled Advancing Psychedelic Clinical Study Design, which aims to explore empirical approaches to address issues in drug development. The U.S. Food and Drug Administration (FDA) together with the Reagan-...

Welcome to Benzinga’s psychedelics headlines roundup. This is our pick of must-read news items from weeks three and four of January 2024. See previous edition Psychedelics Headlines: MDMA & Coping Skills In PTSD, LSD’s Perceived Risks, Knowledge Gaps, Surveys & More  Research...

Welcome to Benzinga's weekly psychedelics headlines roundup. This is our pick of must-read news items from the second week of January 2024.  See previous edition: Psychedelics Headlines: Magic Mushrooms For Sexual Wellbeing, The DEA's Stance, The Therapist's Role & More...

The Drug Enforcement Administration (DEA) has proposed a considerable surplus to the originally-established 2023 production quotas of cannabinoids and psychedelics toward supporting preclinical and clinical research. This is not the first time. In late 2021 and 2022, the DEA increased the...

Cybin’s (NYSE: CYBN) deuterated psychedelics programs received two patent grants from the United States Patent and Trademark Office (USPTO,) and one from the European Patent Office (EP.) Headquartered in Canada and operational in-site as well as in the U.S., the U.K., the Netherlands and...

Psychedelics companies Cybin Inc. (NYSE: CYBN) and Small Pharma Inc. (OTCQB: DMTTF) have completed their August acquisition agreement. Following their arrangement plan under the BC Business Corporations Act, and pursuant to the agreement’s terms, Small Pharma is now a wholly-owned subsidiary...